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Helper T cellactivation by the globular protein antigens studied to date requires
the uptake and intracellular processing of the antigen by an la-expressing APC
releasing a peptide fragment containing the T cell antigenic determinant, which is
transported to and held on the APC surface where the peptide is recognized by the
specific T cell in conjunction with la (1-6). When APC-processing functions are
blocked (2-6) or when Ia-containing planar membranes are substituted for APC
(7), only peptide fragments or denatured proteins, not native proteins, activate T
cells. While the requirement for the APC function inhelper T cell activationis well
documented, the molecular mechanisms underlying this phenomenon remain to be
detailed. Ofparticular interest is thenature ofthe association ofthe antigenic pep-
tide with la and with the TCR that leads to the activation ofthe Tcell. Recent evi-
dence indicates that peptides, but not native antigens, bind to la (8-10), and it has
beensuggested that T cells recognizeapreformedpeptide-Ia complex. Alternatively,
Tcells may facilitate the formation of such a complex (11), leading to their activa-
tion. In addition to la, other APC peptide-binding proteins have been implicated
to play a role in antigen presentation (12, 13), possibly by transporting processed
antigen to the cell surface and facilitating peptide interaction with Ia or the TCR.
In this report, we show that an antigenic peptide fragment ofthe soluble globular
protein antigen, tobacco hornworm moth cytochrome c (THMc)1, residues 92-103
containing an NH2-terminal cysteine (THMcCys92-103), is an extremely effective
Tcell antigen when covalently coupled to antibodies specific for Ig, Ia, or class I
molecules expressed on surfaces of B cells used as APC. Thus, such peptide anti-
body conjugates were effectively presented by H-2k B cells to an I-Ek-restricted T
cell hybrid, in an MHC-restricted fashion, requiring 100-1,000th of the peptide to
reach maximal stimulation, as compared with THMcCys92-103 alone or
THMcCys92-103 coupled to nonspecific Ig. Paraformaldehyde-fixed B cells, which
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are blocked in their processing functions, effectively present the peptide-antibody
conjugates, even though, as previously demonstrated, B cells treated in this fashion
fail to present native cytochrome c covalently coupled to the same Ig-, I-A'-, or Kk-
specific antibodies (14). Presentation is nearly as effective when B cellsare incubated
with the peptide antibody conjugate, and the unbound conjugate is removed before
addition ofT cells as when continuously present in T and B cell containing cultures,
indicating that the stimulatory peptide antibody conjugates are associated with B
cell surfaces. These results demonstrate that a small antigenic peptide covalently
coupled to a larger antibody molecule can be effectively assembled into a stimula-
tory complex with la, even when the peptide antibody conjugates are initially bound
to structures distinct from the Ia molecule recognized by the T cell.
Materials and Methods
Animals.
￿
CBA/J, C57BL/IOJ, and SJL/J female mice, 6-8 wk old, were purchased from
the Jackson Laboratory, Bar Harbor, ME.
Antibodies.
￿
mAbs specific for I-Ak, a mouse IgG2bK antibody produced by the TIB93 cell
line (15), for Kk, a mouse IgG2aK antibody from the HB13 cell line (16), and for I-As, a
mouse IgG2bK antibody derived from the HB4 cell lines (17), were each purified from cul-
ture supernatants as previously described (14). All cell linesare free of mycoplasma contami-
nation, and antibody preparation is endotoxin free. Rabbit antibodies specific for F(ab')2 frag-
ments of mouse antibody (rabbit anti-Ig) were obtained from serum of rabbits immunized
with F(ab')2 fragments of mouse antibody purified by affinity chromatography on mouse-Ig
Sepharose (14). Monovalent Fab fragments ofrabbit anti-Ig were prepared by papain cleavage
ofaffinity-purified antibodies as described (14). The monovalent fragments show a single silver
stained band of 45 kD M, by SDS-PAGE. Nonspecific rabbit Ig was obtained from nonim-
mune rabbit serum by chromatography on Protein ASepharose (14).
Antigens.
￿
THMc92-103 and THMcCys92-103 were synthesized by the solidphase method,
according to the fluorenylmethoxycarbonyl (Fmoc)-t-butyl-strategy (18, 19) as previously de-
scribed (14). Peptides were judged 98% pure by amino acid hydrolysis and HPLC analysis.
THMcCys92-103 was covalently coupled to antibodies that had been modified with the het-
erobifunctional reagent m-maleimidobenzoyl-N-hydroxysuccinimide (MBS) (Pierce Chem-
ical Co., Rockford, IL) as described (14, 20). THMcCys92-103, protected at its cysteine res-
idue sulthydryl group with S-ethylthio (SSET), was iodinated with 1251 by the chloramine
T method (21), and 1251-peptide was added to unlabeled THMcCys92-103 in a ration of 1 :20
to allow monitoring of the efficiencyof the coupling procedure. THMcCys92-103 (10 mg/ml)
in 25 MM P04, pH 8.0, was reduced to remove the SSETprotecting group by addition of
40 mol excess ofdithiothreitol (DTT) (Sigma Chemical Co., St. Louis, MO) and incubation
for 24 h at 25°C. DTT was removed by gel filtration on a Sephadex B-25-150 column
equilibrated in 0.1 M acetic acid. Peptide-containing fractions were pooled and lyophilized.
Peptide was incubated with MBS-modified antibodies (3 mg/ml) (14) in 0.1 M P04, pH 7.0,
with 0.5 M NaCl for 24 h at 4°C, and the peptide-antibody conjugate was separated from
free peptide by chromatography on a Sephadex G-75-40 column (50 cm x 2 cm) equilibrated
in PBS. Peptide antibody conjugates contain N1-2 peptides per antibody molecule and ap-
pear to be monomeric as judged by their behavior on the gel filtration column and by their
mobility in nonreducing SDS-PAGE.
Preparation ofB Cells.
￿
B cells used as APC were prepared from spleen cells of CBA/J mice
by depletion ofRBC by centrifugation on Ficoll-Hypaque gradients and T cells by treatment
with mAbs directed toward Lyt-2, Thy-1, L3T4, and rabbit serum as a source ofcomplement,
as described (22). The resulting cell population was >95% Ig positive and unresponsive to
Con A (22). When indicated, B cellswere fixed by treatment with 0.15% paraformaldehyde
as detailed previously (6).
Measurement of T Cell Activation.
￿
The I-Ek-restricted pigeon cytochrome c-specific T cell
hybrid TPc9.1 secretes IL-2 in response to pigeon cytochrome c presented by H-2k APC (6)CASTEN ET AL .
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and shows a heteroclitic response to THMc and THMc81-103 (23). TPc9.1 cells (5 x 10 4 )
were cocultured with B cells (2 x 10 5 ) and antigen in 0.2 ml cultures in 96-well microtiter
plates in complete medium (22) containing5% FCS, and the culture supernatants were re-
moved 24 h later and assayed for the presence of IL-2 by the ability to maintain the growth
of the IL-2-dependent cell line, CTLL, as previously described (24) . CTLL viability was
determined by the conversion of(3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide (MTT) (Sigma Chemical Co.) to a colored crystalline product absorbing at 570 nm
when dissolved in isopropanol containing 0.04 N HCl, (25) or by the incorporation of
[ 3H]thymidine (6) .
Results
THMcCys92-103-antibody Conjugates Are Effective TCellAntigens.
￿
The ability of the
THMcCys92-103-antibody conjugates to activate I-E'-restricted THMc-specific
TPc9 .1 cells was evaluatedwhen live B cells were used as APC . Because the uncon-
jugated THMcCys92-103 peptide used to make-the peptide antibody conjugates
is antigenic and does not require processing, it was essential for this analysis to en-
sure that the peptide antibody conjugate contained no free peptide . As shown in
Fig . 1, by SDS-PAGE analysis, the THMcCys92-103 normal rabbit Ig conjugate
has been separated from the free peptide in the reaction mixture and contains unde-
tectable free peptide. Similar results were obtained for each peptide antibody conjugate .
B cells were cocultured with irradiated TPc9 .1 cells and graded concentrations of
peptide or peptide-antibody conjugates, and the culture supernatants were tested
24 h later for the presence of IL-2 as a measure ofT cell activation . The halfmax-
imal TPc9.1 response to THMcCys92-103-anti-Ig was achieved with N1/1,000th the
FIGURE 1 . SDS-PAGE and autoradiography of 125I-labeled
THMcCys92-103-antibody conjugates. 1251-labeled THMcCys92-
103 was coupled to nonspecific rabbit Ig, and free peptide was sepa-
rated from the peptide antibody conjugate by gel filtration as
detailed in Materials and Methods . (Lanes 1-3) Peptide-normal
rabbit Ig conjugate after gel filtration at 10, 20, and 40 wg, respec-
tively . (Lanes 4 and 5) Peptide and rabbit antibody reaction mix-
ture before gel filtration at 6 and 60 jig, respectively.174
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FIGURE 2. THMcCys92-103 cova-
lently coupled to anti-Ig antibodies is
a potent Tcell antigen. TPc9.1 cells (5
x 104) were cocultured with live B
cells (2 x 105) as APC and varying
concentrations of THMcCys92-103
(A), THMcCys92-103-rabbit anti-
mouse Ig antibodies (O), or THMc-
Cys92-103-nonspecific rabbit Ig ("),
THMcCys92-103 plus 20 Wg/ml rabbit
anti-mouse antibodies Ig (A), THMc-
Cys92-103 plus 20 wg/ml nonspecific
rabbit Ig (0). Culture supernatants
were removed at 24 h and tested for
their IL-2 content by the MTTassay.
Theconcentration ofTHMcCys92-103
[THMcCys92-103] (,uM)
￿
in the conjugates is shown on the
ordinate.
0.0001
￿
0.01
￿
1 .0
peptide required forunconjugated THMcCys92-103, THMcCys92-103 coupled to
nonspecific rabbit Ig, THMcCys92-103 plus rabbit anti-Ig, or THMcCys92-103 plus
nonspecific rabbit Ig (Fig. 2). Moreover, covalently coupling the THMcCys92-103
peptide to nonspecific rabbit Ig does not affect its antigenicity, as compared with
thefree THMcCys92-103, indicating that thepeptide, when part of alarger protein
structure, is as effective in activating the T cells as the free peptide. Like
THMcCys92-103, the TPc9.1 response to the THMcCys92-103-anti-Ig conjugate
was MHC restricted in that no TPc9.1 activation was observed when B cells were
obtained from C57BL/10J(H-26
) mice, which fail to express an I-E molecule, or
from SJL/J(H-28) mice (Table I). It should be noted that THMcCys92-103 coupled
to I-As-specific antibodies is somewhat more effective than uncongugated
TABLE I
Presentation of THMcCys92-103-antibody Conjugates is MHC Restricted
[THMcCys92-103] required for
5070 maximal T cell response when
presented by B cells from:
TPc9.1 cells (5 x 104) were cultured with splenic Bcells (2 x 105) purified from CBA/J(H-2k),
C57BL/10J(H-2b) or SJL/J(H-2a) mouse spleens, andvarying concentrations of THMcCys92-
103, THMcCys92-103-anti-Ig, THMcCys92-103-anti-I-Ak, THMcCys92-103-anti-Kk, THMc-
Cys92-103-anti-I-A3, or THMcCys92-103-normal rabbit serum Ig. Culture supernatants were
removed 24 hlater andassayed for their IL-2 content by the MTT assay. The results are ex-
pressed as the concentration ofTHMcCys92-103 required to achieve the 50% maximal TPc9.1
cell responses.
Antigen CBA/J(H-2k) C57BL/10J(H-2b)
'UM
SJL/J(H-2$)
THMcCys92-103 1 .0 >10.0 >10.0
THMcCys92-103-anti-Ig 0.001 >0.7 >0.7
THMcCys92-103-anti-I-Ak 0.009 >6.9 >7.0
THMcCys92-103-anti-Kk 0.007 >5.8 >7.0
THMcCys92-103-anti-I-A' 0.1 >6.1 >6.1
THMcCys92-103-NSIg 1 .0 >3.0 >3.0THMcCys92-103 or THMcCys92-103 coupled to nonspecific Ig, reflecting a low
level of crossreactivity of the antibody with the CBA/J B cells (data not shown) .
The increased antigenicity ofthe peptide is also observed whenTHMcCys92-103
is coupled to antibodies specific for I-A' and Kk (Fig . 3) . Thus, the half maximal
TPc9 .1 cell responses to THMcCys92-103-anti-I-Al and to THMcCys92-103-anti-
Kk conjugates were achieved at peptide concentrations 1/100-1/1,000th of that re-
quired forunconjugated THMcCys92-103, THMcCys92-103 coupled to antibodies
specific for I-As, (Fig. 3) or to THMcCys92-103 plus either I-Ak or Kk antibodies
(Fig . 4) . The TPc9.1 response to THMcCys92-103 coupled to I-A' and Kk-specific
antibodies is MHC restricted as B cells from C57BL/IOJ(H-26
) and SJL/J(H-2°)
mice fail to present the conjugates (Table I) . The SJL/J(H-2°) B cells also fail to
present the THMcCys92-103-anti-I-A9 conjugate, indicating that peptide bound to
theAPC surface, in thequantities achieved here, is not sufficient to activate theTPc9 .1
cells in the absence ofthe appropriateMHC molecules . Moreover, the effectivepresen-
tation of THMcCys92-103 antibody conjugates to TPc9 .1 cells does not require
the continued presence of the conjugate, in that B cells incubated with the
THMcCys92-103-anti-Ig antibody conjugate for 2 h in complete medium, and ex-
haustively washed, activated TPc9.1 cells to IL-2 secretion (data not shown) .
FIGURE 3 . THMc92-103 covalently
coupled to antibodies directed against
T
￿
T
￿
Ia and class I molecules activate TPc9 .1
cells. TPc9.1 cells (5 x 10 4) were cocul-
j o y`-~-~'
￿
tured with live B cells (2 x 105) as
--A
￿
O
￿
APC and varying concentrations of o
￿
/
￿
THMcCys2-103 (O), THMcCys92-
-~-~
￿
O/O
￿
103-anti-K?(A), THMcCys92-103-I-
Ak (" ), and THMcCys92-103-anti-
I-A° ("). Culture supernatants were
assayed for their IL-2 content at 24h
by theMTTassay.Theconcentration
0.001
￿
0.100
￿
10.00
￿
oftheTHMcCys92-103 peptide in the
conjugates is shown on the ordinate .
[THMcCys92-103] (AM)
o.1o0
￿
1 .ooo
￿
1o.oo
[THMcCys92-103) (AM)
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FIGURE 4 .
￿
Antibodies specific for I-
Ak and for Kk do not augment the T
cell response to THMcCys92-103 .
TPc9 .1 cells (5 x 104) were cocultured
with B cells (2 x 105) as APC and
THMcCys92-103 ("), at varying con-
centrations or THMcCys92-103 plus
20 ug/ml of: anti-I-A'` antibodies ("),
anti-Kk antibodies (O), and anti-I-A°
antibodies (A). 24h later, supernatants
were assayed for their IL-2 content by
theMTT assay . The concentration of
THMcCys92-103 is shown on the or-
dinate.176
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FIGURE 5.
￿
Paraformaldehyde-fixed Bcells
effectively present THMcCys92-103-anti-
Ig conjugates. B cells were fixed with
pamformaldehyde, and 105 cells were cul-
tured with 5 x 104 TPc9.1 cells and
graded concentrations of either THMc-
Cys92-103-rabbit anti-mouse-Ig anti-
bodies ("), THMcCys92-103-normal
rabbit Ig(A), or MI-104 (O). Culture su-
pernatants were assayed for their IL-2
content by the uptake of [3H]dT by the
CTLL cells. Fixed B cells were unable to
present native PC, yielding 660 ± 30 cpm
and 4,700 t 540 cpm when incubated
[Peptide] (uM)
￿
with 3 and 10 pM PC, respectively.
Augmented Antigenicity of THMcCys92-103-antibody Conjugates Does not Require Pro-
cessing THMcCys92-103 covalently coupled to antibodies specific for Ig, (Fig. 5
and Table II), and for I-A' and Kk (Table II), were nearly as effectively presented
to TPc9.1 cells byparaformaldehyde-fixed B cells as bylive cells, indicatingthat the
peptide antibody complexes donot require processing. That the paraformaldehyde
treatment did indeed block the processing function ofthe B cells is shown by the
inability of fixed cells to present native Pc to TPc9.1 cells (Table II). In addition,
fixedB cellswere previouslyshown (14) tobeincapableofpresentingnative cytochrome
c covalently coupled to the same Ig-, I-Ak-, and K'-specific antibodies used here.
Fixed B cells were comparable with liveB cells in their presentation ofthepeptide
anti-Ig antibody conjugate, which in each case required 1,000-fold less peptide as
TABLE II
Presentation of THMcCys92-103-antibody Conjugates on Live and
Paraformaldehyde-fixed Cells
B cells from CBA/J(H-2k) mice were untreated or fixed with paraformaldehyde
and 2 x 105 cells cultured with 5 x 104 TPc9.1 cells and graded concentrations
of THMcCys92-103, THMcCys92-103 coupled to antibody specific for Ig, I-Ak,
Kk, I-A', or to monovalent Fabfragments of rabbit anti-mouse antibody (Fab-
anti-Ig) or with native PC. The culture supernatants were removed 24 hlater,
and their IL-2 content was determined by the MTT assay. The concentration
of antigen, either THMcCys92-103 or PC, required to achieve half maximal
T cell responses is given.
Antigen
[Antigen]
5070
when
Live APC
required for
maximal T cell response
presented by:
Fixed APC
uM
THMcCys92-103 1.1 4.0
THMcCys92-103-anti-Ig 0.002 0.004
THMcCys92-103-anti-I-A' 0.001 0.01
THMcCys92-103-anti-Kk 0.003 0.02
THMcCys92-103-anti-I-Al 0.1 0.1
THMcCys92-103-Fab-anti-Ig 0.01 0.01
PC 3.0 >10CASTEN ET AL.
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compared with THMcCys92-103 alone (Table II) or with Pc81-104 alone (Fig. 5).
Although fixed B cells present the peptide anti-I-A' and peptide anti-Kk antibody
conjugates in an enhanced fashion requiring 1/400th the concentration of peptide
alone, the presentation is less effective than that by live B cells. Fixed cells require
-10-fold more peptide to achieve maximal T cell responses as compared with live
B cells . At present, the basis of the decreased ability of fixed B cells to present the
peptide anti-Ia and peptide anti-class I antibody conjugate is not understood .
THMc92-103 Coupled to Monovalent Antibodies Is a Less E,jfective Antigen as Compared
With THMcCys92-103-divalent Antibody Conjugates. To determine the contribution
of antibody valency to the effectiveness ofpeptide antibody conjugates,THMc92-103
was coupled to monovalent Fab fagments of rabbit anti-Ig and the TPc9 .1 response
compared with that ofTHMcCys92-103 alone (Table II) . The presentation ofpep-
tide coupled to monovalent fragments was enhanced -100-fold as compared with
THMcCys92-103 alone, which is 10-fold less effective than peptide coupled to intact
bivalent rabbit anti-Ig antibodies. Thiswas the case whether live or pamformaldehyde-
fixed B cells were used asAPC (Table II), suggesting that the efficacy of the bivalent
conjugates may not be due to a need to patch Ig on the B cells surface but rather
to the increased advidity ofthe conjugate for the B cell's surface afforded by bivalent
binding .
Discussion
Although the general features of antigen processing and presentation that lead
to activation of la-restricted helper T cells are well documented, the molecular mech-
anisms underlying this phenomenon remain to be detailed. Of particular interest
is the mechanism by which processed antigens or exogenously added antigenic pep-
tides are held on the APC surface and recognizedby the specificT cell in conjunc-
tion with Ia. Babbitt et al ., (8) and Buus et al . (9, 10) demonstrated that peptides,
but not native antigens, bind to purified Ia in detergent solution with a Kd of-2 x
10'M and suggest that the formation of a peptide-lacomplex may be a necessary
first step in the activation of helper T cells . Subsequent studies by Watts et al. (26)
indicated that -1% ofpurified Ia incorporated into planarmembranes bound pep-
tide, in a nearly irreversible fashion, and activated specific T cells . However, earlier
studies (11) indicated that peptide did not associate with Ia in planar membranes
in the absence of a specific T cell, but did so when such T cells were present, sug-
gesting that the TCR played a role in assembling an Ia-peptide complex . Indeed,
APC structures, distinct from Ia, have been demonstrated to bind peptide and to
play a role in antigen processing and /or presentation (12, 13), possibly by trans-
porting processed antigen to the APC surface and facilitating its interaction with
Ia and the TCR .
In this report, weshow that theT cell-antigenic peptide, THMcCys92-103, cova-
lently coupled to antibodies specific for the B cell surface structures Ig, Ia, and Class
I are effectively presented to specificT cells by B cells asAPC, and that such presen-
tation does not require internalization or processing of the peptide antibody con-
jugate . We have previously demonstrated that native cytochrome c covalently cou-
pled to thesame antibodies specific for either Ig, Ia, or class I were extremely effective
antigens in vitro, activating cytochrome c-specificT cells in an MHC-restricted fashion
when present in 1/1,000th the concentration required of cytochrome c alone,178
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cytochrome c coupled to nonspecific Ig, or cytochrome c plus unconjugated anti-
bodies (14) . However, presentation of such conjugates, like the native cytochrome
c, required processing, in that the conjugates are notpresented by paraformaldehyde-
fixedBcells. Taken together, these results andthosepresented in this report demon-
strate thatasmall 12-amino acid peptide covalently coupled to alarger macromolecule
such as antibody does not diminish its ability to be assembled into a stimulatory
complex with Ia and the TCR, and that peptides bound initially to surface struc-
tures other than Ia are extremely effectiveT cell antigens . A similar observation,
concerning the antigenicity of peptides that are part oflarge macromolecules, was
made byLorenz and Allen (27), who showed that theTcell recognition of aCOOH-
terminal antigenic determinant of the 340-kD protein fibrinogen does not require
processing .
An important question that remains to be answered is thelocation of the stimula-
tory peptide on theB cell surfacewhen it is recognized by theT cell . It would seem
unlikely that the peptide antibody conjugate undergoes a significant degree of pro-
teolysis on theB cell surface, allowing the dissociation of the peptide in quantities
sufficient for T cell activation . If this were the case, one would anticipate that the
native cytochrome c antibody conjugates would be active, to some degree, in the
absence of processing . Indeed, if active proteolysis occurs at theB cell surface, the
peptide itself would be extremely sensitive to degradation and consequent loss of
activity. It has been shown that removal of the COOH-terminal lysine residues de-
stroys the peptide's antigenic activity, and peptides shorter than 10 amino acids are
insufficient to activate the T cell . Therefore, any postulated proteolysis would re-
quire the removal of the peptide from the Ig with no degradation of the peptide
itself. However, the peptide antibody conjugatemay not be bound to the structure
forwhichtheantibody is specific at thetime it is recognized by theTcell in conjunc-
tion with Ia . The ability to pulse the B cell with the peptide antibody conjugate
indicatesthat conjugates bound to theBcell are sufficient forTcell activation . However,
the peptide antibody conjugate may be transferred from its binding site to a site
on Ia or theTCR before T cell activation . Further studies, using chemical cross-
linking reagents, may allow an elucidation of the position of the peptide antibody
conjugate on the B cell surface.
The observation presented here, that short antigenic peptides covalently coupled
to antibodies are effectiveT cellsantigens in vitro, may providea means to augment
peptide immunogenicity in vivo. We have previouslyshownthat native cytochrome
c covalently coupled to antibody specific for mouse Ig, which is -1,000-fold more
effective as an antigenin vitro as compared with cytochrome ccoupled to nonspecific
Ig (14), is also immunogenic in vivo when administered to mice intravenously in
saline, conditions under which native cytochrome c fails to induce an antibody re-
sponse (28) . Results of studies to assess the efficacy ofthe THMcCys92-103 in vivo
should be of interest in this regard .
Summary
The helper T cell recognition of soluble globular protein antigens requires that
the proteins be processed by anAPC, releasing a peptide that is transportedto and
held on theAPC surface where it is recognized by the specificT cell in conjunction
with Ia. When cellular processing functions are blocked, APC lose their ability toCASTEN ET AL.
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presentnative antigens whileretaining the capacity to activateTcellswhenprovided
with a cognate peptide fragment that contains the T cell antigenic determinant. In
this report, we show that a peptide fragment ofthe soluble globularprotein antigen
tobacco hornworm moth cytochrome c, residues 92-103 containing an additional
N112-terminal cysteine residue (THMcCys92-103), is effectively presentedby B cells
to an I-Ek-restricted, THMc-specific T cell hybrid when covalently coupled to anti-
bodies specific for B cell surface Ig, Ia (Ak), or class I (Kk). Maximal activation ofthe
Tcells to theTHMcCys92-103-antibody conjugates isachievedwith 1/100-1/1,000th
ofthe peptide required using unconjugated THMcCys92-103 or THMcCys92-103
coupled to nonspecific antibody. The T cell response to the peptide antibody con-
jugates is MHC restricted, but unlike native cytochrome c-antibody conjugates,
THMcCys92-103-antibody conjugates do notrequireprocessingandcanbepresented
by paraformaldehyde-fixed B cells. The THMcCys92-103-antibody conjugate are
nearly aseffectivewhenincubatedwith B cells, and the unbound conjugates washed
away before addition ofT cells as when continuously present in culturewith T cells
and B cells, indicating that the active peptide antibody conjugate is associated at
theBcell surface. Thepresentation ofTHMcCys92-103 coupledto monovalent Fab
fragments of rabbit anti-Ig antibodies is less effective than that ofthe peptide cou-
pled to bivalent antibody when either live or fixed B cells are APC, indicating that
the avidity for the APC surface afforded by bivalent binding may be important in
the conjugate's antigenicity. The results presented here indicate that a Tcell-anti-
genic peptide, covalently coupled to alarger antibody molecule, can be readily rec-
ognized by an la-restricted helper T cell in the absence of processing. Moreover,
the ability ofthe peptide to bind to B cell surfaces greatly augments the peptide's
antigenicity, even when the binding is to structures distinct from the la molecule
required for T cell activation.
Receivedfor publication 19 January 1988 and in revisedform 22 March 1988.
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